Atnaujinkite slapukų nuostatas

Non-Steroidal Anti-Inflammatory Drugs: Iarc Handbooks on Cancer Prevention [Minkštas viršelis]

  • Formatas: Paperback / softback, 202 pages, aukštis x plotis: 240x160 mm, weight: 42 g, 9 line figures, bibliography
  • Serija: IARC Nonserial Publication v. 1
  • Išleidimo metai: 01-Nov-1997
  • Leidėjas: International Agency for Research on Cancer
  • ISBN-10: 9283230019
  • ISBN-13: 9789283230014
Kitos knygos pagal šią temą:
Non-Steroidal Anti-Inflammatory Drugs: Iarc Handbooks on Cancer PreventionDidesnis paveikslėlis
  • Formatas: Paperback / softback, 202 pages, aukštis x plotis: 240x160 mm, weight: 42 g, 9 line figures, bibliography
  • Serija: IARC Nonserial Publication v. 1
  • Išleidimo metai: 01-Nov-1997
  • Leidėjas: International Agency for Research on Cancer
  • ISBN-10: 9283230019
  • ISBN-13: 9789283230014
Kitos knygos pagal šią temą:
Pastovi nuoroda: https://www.kriso.lt/db/9789283230014.html
Raktažodžiai:
The objective of the Handbooks programme is the preparation of critical reviews and evaluations of evidence on the cancer-preventive and other relevant properties of a wide range of potential cancer-preventive agents and strategies by international working groups of experts.

In this volume on non-steroidal anti-inflammatory drugs the following drugs are reviewed: Aspirin, Sulindac, Piroxicam and Indomethacin. For each drug, their chemical and physical characteristics, occurrence, production, use, analysis and human exposure, metabolism, kinetics and genetic variation are studied, as well as their cancer-preventive effects, other beneficial effects, carcinogenicity and other toxic effects. A summary of data and recommendations for research are provided at the end.
List of Participants 1(2)
Preamble 3(12)
General Remarks
15(28)
1. Introduction
15(1)
1.1 Observational studies of colorectal cancer
16(1)
1.2 Studies in experimental animals
16(1)
1.3 Drugs considered
16(1)
2. Colorectal cancer
16(3)
2.1 Descriptive epidemiology
16(1)
2.2 Biology of colorectal cancer in humans
16(1)
2.3 Experimental studies
17(2)
3. Pharmacological action of non-steroidal anti-inflammatory drugs
19(5)
3.1 Synthesis and action of prostaglandins
19(1)
3.2 Prostaglandins and human tumours
20(3)
3.3 Alternative mechanisms
23(1)
3.3.1 Mechanisms independent of prostaglandins
23(1)
3.3.2 Effects of non-cancerous tissues
23(1)
3.3.3 Cytochrome P450
24(1)
4. Adverse effects
24(4)
4.1 Ulceration
25(1)
4.1.1 Age
25(1)
4.1.2 History of ulcer disease
25(1)
4.1.3 Helicobacter pylori
26(1)
4.1.4 Corticosteroids
26(1)
4.1.5 Anticoagulants
26(1)
4.2 Asthma
26(1)
4.3 Drug interactions
26(1)
4.4 Taking account of toxic effects
27(1)
4.5 Mitigating side-effects
27(1)
5. Recommendations for research
28(1)
6. Procedures used
29(1)
7. References
29(14)
Aspirin
43(60)
1. Chemical and physical characteristics
43(1)
1.1 Name
43(1)
1.2 Structural and molecular formulae and relative molecular mass
43(1)
1.3 Physical and chemical properties
43(1)
1.4 Technical products
43(1)
2. Occurrence, production, use, analysis and human exposure
44(2)
2.1 Occurrence
44(1)
2.2 Production
44(1)
2.3 Use
44(1)
2.4 Analysis
44(1)
2.5 Human exposure
45(1)
3. Metabolism, kinetics and genetic variation
46(4)
3.1 Human studies
46(4)
3.1.1 Metabolism
46(1)
3.1.2 Pharmacokinetics
47(3)
3.2 Experimental models
50(1)
3.3 Genetic variation
50(1)
4. Cancer-preventive effects
50(20)
4.1 Human studies
50(14)
4.1.1 Studies of colorectal cancer
50(8)
4.1.2 Studies of sporadic adenomatous polyps in the colon
58(2)
4.1.3 Studies of oesophageal and gastric cancers
60(2)
4.1.4 Studies of cancers other than in the digestive tract
62(1)
4.1.5 Issues in interpreting the evidence for prevention of colorectal cancer
63(1)
4.2 Experimental models
64(3)
4.2.1 Experimental animals
64(3)
4.2.2 In-vitro models
67(1)
4.3 Mechanisms of chemoprevention
67(3)
4.3.1 Inhibition of carcinogen activation
67(1)
4.3.2 Inhibition of cell proliferation
68(1)
4.3.3 Apoptosis
68(1)
4.3.4 Immune surveillance
68(2)
5. Other beneficial effects
70(2)
5.1 Antiplatelet effects
70(1)
5.1.1 Background
70(1)
5.1.2 Mechanism
70(1)
5.1.3 Secondary prevention in populations at high risk for cardiovascular events
70(1)
5.1.4 Primary prevention in populations at average risk for cardiovascular events
71(1)
5.1.5 Lowest effective dose for prevention of cardiovascular events in high-risk populations
71(1)
5.2 Alzheimer disease
71(1)
5.3 Reproductive outcomes
71(1)
6. Carcinogenicity
72(1)
6.1 Human studies
72(1)
6.1.1 Renal cancer
72(1)
6.1.2 Haematopoietic malignancies
73(1)
6.1.3 Childhood cancer
73(1)
6.2 Experimental animals
73(1)
7. Other toxic effects
73(14)
7.1 Adverse effects
73(11)
7.1.1 Humans
73(8)
7.1.2 Experimental animals
81(3)
7.2 Genetic and related effects
84(3)
7.2.1 Humans
84(1)
7.2.2 Experimental models
84(3)
8. Summary of data
87(2)
8.1 Chemistry, occurrence and human exposure
87(1)
8.2 Metabolism and kinetics
87(1)
8.3 Cancer-preventive effects
87(1)
8.3.1 Humans
87(1)
8.3.2 Experimental animals
88(1)
8.3.3 Mechanism of action
88(1)
8.4 Other beneficial effects
88(1)
8.5 Carcinogenicity
88(1)
8.5.1 Humans
88(1)
8.5.2 Experimental animals
88(1)
8.6 Toxic effects
88(1)
8.6.1 Humans
88(1)
8.6.2 Experimental animals
89(1)
9. Recommendations for research
89(1)
10. Evaluation
90(1)
10.1 Cancer-preventive activity
90(1)
10.1.1 Humans
90(1)
10.1.2 Experimental animals
90(1)
10.2 Overall evaluation
90(1)
11. References
90(13)
Sulindac
103(24)
1. Chemical and physical characteristics
103(1)
1.1 Name
103(1)
1.2 Structural and molecular formulae and relative molecular mass
103(1)
1.3 Physical and chemical properties
103(1)
1.4 Technical products
103(1)
2. Occurrence, production, use, analysis and human exposure
103(1)
2.1 Occurrence
103(1)
2.2 Production
103(1)
2.3 Use
104(1)
2.4 Analysis
104(1)
2.5 Human exposure
104(1)
3. Metabolism, kinetics and genetic variation
104(2)
3.1 Human studies
104(1)
3.1.1 Metabolism
104(1)
3.1.2 Pharmacokinetics
104(1)
3.2 Experimental models
105(1)
3.3 Genetic variation
106(1)
4. Cancer-preventive effects
106(9)
4.1 Human studies
106(2)
4.1.1 Studies of adenomatous polyps in patients with familial adenomatous polyposis
106(2)
4.1.2 Randomized clinical trial of sporadic adenomatous polyps
108(1)
4.1.3 Case studies of treatment for desmoid tumours
108(1)
4.2 Experimental models
108(6)
4.2.1 Experimental animals
108(6)
4.2.2 In-vitro models
114(1)
4.3 Mechanisms of chemoprevention
114(1)
4.3.1 Effects on cell proliferation and apoptosis
114(1)
4.3.2 Effects on oncogene expression
115(1)
5. Other beneficial effects
115(1)
6. Carcinogenicity
115(1)
6.1 Humans
115(1)
6.2 Experimental animals
115(1)
7. Other toxic effects
115(2)
7.1 Adverse effects
115(2)
7.1.1 Humans
115(2)
7.1.2 Experimental animals
117(1)
7.2 Genetic and related effects
117(1)
8. Summary of data
117(1)
8.1 Chemistry, occurrence and human exposure
117(1)
8.2 Metabolism and kinetics
118(1)
8.3 Cancer-preventive effects
118(1)
8.3.1 Humans
118(1)
8.3.2 Experimental animals
118(1)
8.3.3 Mechanism of action
118(1)
8.4 Other beneficial effects
118(1)
8.5 Carcinogenicity
118(1)
8.6 Toxic effects
118(1)
8.6.1 Humans
118(1)
8.6.2 Experimental animals
118(1)
9. Recommendations for research
118(1)
10. Evaluation
119(1)
10.1 Cancer-preventive activity
119(1)
10.1.1 Humans
119(1)
10.1.2 Experimental animals
119(1)
10.2 Overall evaluation
119(1)
11. References
119(8)
Piroxicam
127(24)
1. Chemical and physical characteristics
127(1)
1.1 Name
127(1)
1.2 Structural and molecular formulae and relative molecular mass
127(1)
1.3 Physical and chemical properties
127(1)
1.4 Technical products
127(1)
2. Occurrence, production, use, analysis and human exposure
127(1)
2.1 Occurrence
127(1)
2.2 Production
127(1)
2.3 Use
127(1)
2.4 Analysis
128(1)
2.5 Human exposure
128(1)
3. Metabolism, kinetics and genetic variation
128(5)
3.1 Human studies
128(4)
3.1.1 Metabolism
128(1)
3.1.2 Pharmacokinetics
128(4)
3.2 Experimental models
132(1)
3.2.1 Metabolism
132(1)
3.2.2 Pharmacokinetics
132(1)
3.3 Genetic variation
133(1)
4. Cancer-preventive effects
133(8)
4.1 Human studies
133(1)
4.2 Experimental models
134(5)
4.2.1 Experimental animals
134(4)
4.2.2 In-vitro models
138(1)
4.3 Mechanisms of chemoprevention
139(2)
4.3.1 Preneoplastic lesions
139(1)
4.3.2 Inhibition of carcinogen activation
139(1)
4.3.3 Effects on cell proliferation and apoptosis
140(1)
4.3.4 Immune surveillance
140(1)
5. Other beneficial effects
141(1)
6. Carcinogenicity
141(1)
6.1 Humans
141(1)
6.2 Experimental animals
141(1)
7. Other toxic effects
141(2)
7.1 Adverse effects
141(1)
7.1.1 Humans
141(1)
7.1.2 Experimental animals
141(1)
7.2 Genetic and related effects
142(1)
7.2.1 Humans
142(1)
7.2.2 Experimental models
142(1)
8. Summary of data
143(1)
8.1 Chemistry, occurrence and human exposure
143(1)
8.2 Metabolism and kinetics
143(1)
8.3 Cancer-preventive effects
143(1)
8.3.1 Humans
143(1)
8.3.2 Experimental animals
143(1)
8.3.3 Mechanism of action
143(1)
8.4 Other beneficial effects
143(1)
8.5 Carcinogenicity
143(1)
8.6 Toxic effects
143(1)
8.6.1 Humans
143(1)
8.6.2 Experimental animals
143(1)
9. Recommendations for research
143(1)
10. Evaluation
144(1)
10.1 Cancer-preventive activity
144(1)
10.1.1 Humans
144(1)
10.1.2 Experimental animals
144(1)
10.2 Overall evaluation
144(1)
11. References
144(7)
Indomethacin
151(48)
1. Chemical and physical characteristics
151(1)
1.1 Name
151(1)
1.2 Structural and molecular formulae and relative molecular mass
151(1)
1.3 Physical and chemical properties
151(1)
1.4 Technical products
151(1)
2. Occurrence, production, use, analysis and human exposure
151(1)
2.1 Occurrence
151(1)
2.2 Production
151(1)
2.3 Use
152(1)
2.4 Analysis
152(1)
2.5 Human exposure
152(1)
3. Metabolism, kinetics and genetic variation
152(5)
3.1 Human studies
152(4)
3.1.1 Metabolism
152(1)
3.1.2 Pharmacokinetics
152(4)
3.2 Experimental models
156(1)
3.3 Genetic variation
157(1)
4. Cancer-preventive effects
157(19)
4.1 Human studies
157(1)
4.1.1 Studies of cancer occurrence
157(1)
4.1.2 Studies of other relevant end-points
158(1)
4.2 Experimental models
158(14)
4.2.1 Experimental animals
158(13)
4.2.2 In-vitro models
171(1)
4.3 Mechanisms of chemoprevention
172(4)
4.3.1 Inhibition of carcinogen activation
172(1)
4.3.2 Effects on cell proliferation and apoptosis
172(3)
4.3.3 Immune surveillance
175(1)
5. Other beneficial effects
176(1)
6. Carcinogenicity
176(1)
6.1 Humans
176(1)
6.2 Experimental animals
176(1)
7. Other toxic effects
177(7)
7.1 Adverse effects
177(6)
7.1.1 Humans
177(1)
7.1.2 Experimental animals
178(5)
7.2 Genetic and related effects
183(1)
7.2.1 Humans
183(1)
7.2.2 Experimental models
183(1)
8. Summary of data
184(1)
8.1 Chemistry, occurrence and human exposure
184(1)
8.2 Metabolism and kinetics
184(1)
8.3 Cancer-preventive effects
184(1)
8.3.1 Humans
184(1)
8.3.2 Experimental animals
184(1)
8.3.3 Mechanism of action
184(1)
8.4 Other beneficial effects
184(1)
8.5 Carcinogenicity
184(1)
8.5.1 Humans
184(1)
8.5.2 Experimental animals
184(1)
8.6 Toxic effects
184(1)
8.6.1 Humans
184(1)
8.6.2 Experimental animals
185(1)
9. Recommendations for research
185(1)
10. Evaluation
185(1)
10.1 Cancer-preventive activity
185(1)
10.1.1 Humans
185(1)
10.1.2 Experimental models
185(1)
10.2 Overall evaluation
185(1)
11. References
185(14)
Appendix
1. The concept of activity profiles of antimutagens		 199(3)
Appendix
2. Definitions of test codes		 202